Nautilus Biotechnology, Inc.
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| – | -87.3% | +358.5% | +368.7% | -12.1% | -12.7% | -20.6% | -21.3% | |
| – | +1,173.3% | +357.8% | +349.7% | -46.4% | -5.5% | -24.9% | -20.2% | |
| – | -50.3% | +6,052.4% | +407.1% | -38.3% | -83.1% | +42.5% | -55.2% | |
| – | -100.0% | +360.7% | +350.5% | -46.6% | -6.0% | -25.1% | -20.4% | |
| – | – | +455.2% | -60.0% | +49.0% | – | – | – | |
| – | -99.7% | +23,314.7% | -69.6% | +0.7% | +14.5% | -15.4% | +0.4% | |
| – | +9,700.0% | +515.9% | +92.6% | +16.8% | +34.3% | -16.3% | +4.2% | |
| – | – | – | -34.4% | +105.3% | +77.7% | +15.8% | -6.5% | |
| – | – | +62.6% | +266.6% | -26.2% | +28.9% | -39.8% | -4.5% | |
| – | +261.0% | -264.6% | – | -13.4% | -15.7% | -21.3% | -24.8% | |
| – | -2,447.0% | – | – | – | – | – | – | |
| – | -15.6% | +445.1% | +155.4% | +47.5% | +0.3% | +0.4% | +0.7% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.